Wed, Sep 04, 2024
The city-based drug maker in a statement said the eGenesis Genome Engineering and Production platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant.
More >
Thu, Aug 29, 2024
The drug firm believes it is the first company to have filed a substantially-complete ANDA containing a Paragraph IV Certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of potential launch of the product under certain circumstances.
Fri, Jul 12, 2024
Budget My Pick ; This announcement in the budget will do wonders. Why did Sunny Aggarwal of SBI Securities advise to invest in Natco Pharma today?
Fri, May 31, 2024
In a statement on Thursday, Natco Pharma said: "Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces submission of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with the U.S. Food and Drug Administration (FDA) for the generic version of Rimegepant Sulfate tablet Eq 75mg base strength."
Tue, May 28, 2024
Today Anil Singhvi gave buying opinion in United Spirits & Natco Pharma. What are stoploss and targets?
Sun, May 26, 2024
Foreign portfolio investors (FPIs) have dramatically boosted their selling activity in Indian stock markets since May, with a total investment of Rs 22,046 crore.
Fri, Feb 16, 2024
Natco Pharma share price: At close, shares of Natco Pharma stood at Rs 1,027 apiece, up 15.8 per cent, or Rs 1,40.15.
Wed, Feb 14, 2024
Jain Saab's GEMS: Why did Sandeep Jain choose Natco Pharma today? Know the company's fundamentals, bullish triggers and targets from Sandeep Jain...
Tue, Nov 14, 2023
The Hyderabad-based drug firm had reported a net profit of Rs 57 crore in the July-September period of last fiscal.
Thu, Aug 31, 2023
Natco Pharma's move to invest in ISCA Inc. mirrors its dedication to innovation and environmentally conscious practices. The investment aligns with Natco Pharma's pursuit of expansion and its support for sustainable agricultural solutions.
Wed, Aug 09, 2023
The drugmaker said it has recorded consolidated total revenue of Rs 1160.2 crore for the first quarter, as against Rs 918.9 crore for the same period last year, reflecting a growth of 26.3 per cent.
Fri, Jun 16, 2023
The US Food and Drug Administration (USFDA) granted final approval to the abbreviated new drug application (ANDA) for Tipiracil Hydrochloride and Trifluridine Tablets, the generic version of Lonsurf sold in the US by Taiho Oncology Inc, Natco said in a regulatory filing.
Wed, Mar 08, 2023
Natco Pharma shares buyback: Drugmaker through an exchange filing said that it plans to buy back 30 lakh shares which is 1.64 per cent of the paid-up equity shares of the company.
Thu, Feb 09, 2023
Q3 Results 2023: More listed companies announced their December quarter results on Thursday.
Mon, May 30, 2022
Q4 Results 2022: Listed companies including Sun Pharmaceuticals, Natco Pharma and Omaxe today announced their March quarter results. Here are key highlights of the quarterly earnings
Tue, Mar 08, 2022
At 10:40 am, the scrip gained over 3 per cent to Rs 872.45 per share, as compared to 0.15 per cent decline in the S&P BSE Sensex.
Thu, Nov 11, 2021
Natco Pharma Ltd on Thursday said its consolidated net profit for the quarter ended September 30, 2021, was down by 68.07 per cent to Rs 65.1 crore. It was 203.90 crore in the same period last fiscal.
Fri, Jul 31, 2020
Market analyst Simi Bhaumik today recommended three mid-cap stocks for investors to buy to generate high returns. In today’s edition of Special Mid Cap stocks show with Zee Business Managing Editor Anil Singhvi, Bhaumik picked stocks with long term, positional medium term and long term view. See which stocks were picked by her (#SPLMidcapStocks)
Sun, Jun 09, 2019
"...The second driver will be Brazil, so Brazil did not do well for many years, so we had some very good launches this year and so that should drive earnings," he said replying to a query during a recently held Earnings Call of the company.
Wed, Oct 04, 2017
With this blockbuster performance, the company's stock has reached nearly two-months high. The last time, Natco's share travelled over Rs 900-mark was on August 08, 2017.
Wed, Jan 25, 2017
Shares of Natco Pharma dropped 0.22% on NSE Nifty after the company said that USFDA conducted an inspection at its pharmaceutical factory in Kothur, near Hyderabad between January 16-24, 2017.
Fri, Jun 03, 2016
The company's stock soared 8.54% to settle at Rs 518.35 on the Bombay Stock Exchange (BSE).
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
